Abeona Therapeutics Inc (ABEO)
NASDAQ:ABEO
Want to see ABEO full AI Analyst Report?
Top Page
Abeona Therapeutics
(NASDAQ:ABEO)
Select Model
Select Model
Rating:57Neutral
Price Target:
$6.00
▲(9.09% Upside)
Action:Reiterated
Date:05/14/26
The score is primarily held back by persistent operating losses and substantial cash burn despite improving revenue and a manageable leverage profile. Offsetting this, technicals are moderately positive and the earnings call supports improving commercial execution and payer access, though expense growth and cash decline remain meaningful near-term risks. Valuation provides limited support due to a negative P/E and no dividend.
Positive Factors
Commercial revenue traction
Sustained early commercial receipts and a meaningful TTM revenue rebound indicate the company is moving beyond purely clinical-stage economics. Durable revenue growth and solid gross margins help reduce reliance on financing, support reinvestment in operations, and make future scaling and payer negotiations structurally easier over the next 2–6 months.
Negative Factors
Persistent cash burn
Substantial negative operating and free cash flows mean the business remains reliant on external funding. Even with improving revenue, continued cash burn increases dilution and constrains strategic flexibility, making sustained investment or unexpected setbacks potentially damaging to operations and timelines over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial revenue traction
Sustained early commercial receipts and a meaningful TTM revenue rebound indicate the company is moving beyond purely clinical-stage economics. Durable revenue growth and solid gross margins help reduce reliance on financing, support reinvestment in operations, and make future scaling and payer negotiations structurally easier over the next 2–6 months.
Read all positive factors
Abeona Therapeutics (ABEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$310.05M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.28
Shares Outstanding56,995,144
10 Day Avg. Volume1,302,904
30 Day Avg. Volume1,146,961
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue18.70
Enterprise Value/Gross Profit36.01
Enterprise Value/Ebitda4.08
Forecast
1Y Price Target
$20.67Price Target Upside275.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$65.76M
Abeona Therapeutics Business Overview & Revenue Model
Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical...
How the Company Makes Money
Abeona Therapeutics does not have consistently disclosed, product-based commercial revenue as a primary earnings source; as a clinical-stage biotech, it has historically funded operations mainly through financing activities (e.g., equity offerings...
Abeona Therapeutics Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call presents clear early commercial momentum for ZEVASKYN (notable revenue acceleration, 95% published commercial coverage, growing QTC network and manufacturing success with no harvest failures) and meaningful pipeline advancement with the in-licensed PSMA SIR-T program. Offsetting these positives are elevated operating expenses (notably SG&A), a larger reported net loss driven partly by a $7M upfront license payment, a declining cash balance, and operational / payer timing risks (variable biopsy lead times and lengthy insurance approvals for out-of-state Medicaid). On balance, the positives — strong initial revenue growth, payer coverage, successful manufacturing outcomes and a targeted oncology asset with limited near-term spend — outweigh the near-term financial and operational challenges.Positive Updates
Early Commercial Revenue Traction
Net product revenue of $8.7M in Q1 2026 driven by three commercially insured patients treated in the quarter, up $6.3M vs. $2.4M in Q4 2025 (≈+262.5% quarter-over-quarter).
Negative Updates
Increased Net Loss
Net loss of $17.1M ($0.30 per share) in Q1 2026 versus $12.0M ($0.24 per share) in Q1 2025, an increase of $5.1M (≈+42.5%), primarily reflecting commercial investment and the $7M PSMA licensing transaction.
Read all updates
Q1-2026 Updates
Positive
Negative
Early Commercial Revenue Traction
Net product revenue of $8.7M in Q1 2026 driven by three commercially insured patients treated in the quarter, up $6.3M vs. $2.4M in Q4 2025 (≈+262.5% quarter-over-quarter).
Read all positive updates
Company Guidance
Management's guidance focused on near‑term launch cadence and measured pipeline spend: Q1 product revenue was $8.7M from three commercial treatments (five patients treated since the Dec‑2025 launch), with one patient treated so far this quarter, one in manufacturing and six additional patients expected to be biopsied this quarter (four already scheduled) — manufacturing turnaround ~23–24 days (observed 23–26 days) — and several of these could fall into Q2; the company has six active QTCs, is targeting seven QTCs in 2026 (with a longer‑term target of ~9–10 centers) and expects steady‑state throughput of roughly one patient/month per QTC, a near‑term identified pool of >100 patients and active engagement with 45 physicians, with payer coverage published for 95% of commercially covered lives and an anticipated payer mix of ~60% commercial / ~30–33% Medicaid. Financial guidance: cost of sales in Q1 was $2.7M, R&D $9.6M (including a $7M upfront PSMA license payment), SG&A $19.5M, net loss $17.1M ($0.30/share), cash and short‑term investments $168.3M (vs. $191.4M YE2025); management expects gross‑to‑net in the mid–to‑upper teens as volumes normalize, minimal PSMA R&D this year (low single‑digit millions), a pre‑IND meeting June 3, 2026 and IND/first‑in‑human studies targeted in H2 2027, and stated monthly profitability could be achievable as early as June depending on biopsy/treatment cadence.Abeona Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.54M | 5.82M | 0.00 | 3.50M | 1.41M | 3.00M |
| Gross Profit | 7.55M | 4.29M | -2.91M | 1.90M | 964.00K | 3.00M |
| EBITDA | 66.64M | -85.89M | -56.62M | -50.57M | -34.38M | -76.82M |
| Net Income | 66.14M | 71.18M | -63.73M | -54.19M | -39.70M | -84.94M |
Balance Sheet | ||||||
| Total Assets | 198.49M | 219.57M | 108.93M | 64.00M | 64.21M | 79.59M |
| Cash, Cash Equivalents and Short-Term Investments | 168.27M | 191.40M | 97.72M | 52.23M | 52.15M | 45.02M |
| Total Debt | 23.17M | 24.97M | 23.05M | 5.40M | 7.63M | 9.38M |
| Total Liabilities | 53.55M | 60.35M | 64.90M | 49.18M | 37.45M | 37.22M |
| Stockholders Equity | 144.94M | 159.22M | 44.03M | 14.83M | 26.76M | 42.37M |
Cash Flow | ||||||
| Free Cash Flow | -85.24M | -84.30M | -58.46M | -37.34M | -43.61M | -69.82M |
| Operating Cash Flow | -77.73M | -76.33M | -56.02M | -37.01M | -43.48M | -65.67M |
| Investing Cash Flow | 105.78M | 105.03M | -39.24M | 208.00K | -23.96M | 66.06M |
| Financing Cash Flow | 17.05M | 26.04M | 104.14M | 37.06M | 43.17M | 24.86M |
Abeona Therapeutics Technical Analysis
Positive
5.50
Price Trends
5.16
Positive
5.15
Positive
5.35
Positive
Market Momentum
0.04
Positive
49.81
Neutral
38.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABEO, the sentiment is Positive. The current price of 5.5 is below the 20-day moving average (MA) of 5.58, above the 50-day MA of 5.16, and above the 200-day MA of 5.35, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 49.81 is Neutral, neither overbought nor oversold. The STOCH value of 38.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABEO.
Abeona Therapeutics Risk Analysis
Abeona Therapeutics disclosed 48 risk factors in its most recent earnings report. Abeona Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Abeona Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $310.05M | -3.71 | 41.40% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $233.12M | -1.70 | -2781.56% | ― | 289.94% | 16.60% | |
50 Neutral | $776.48M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
48 Neutral | $292.85M | -4.17 | -107.23% | ― | ― | ― | |
41 Neutral | $164.64M | -9.09 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
ABEO
Abeona Therapeutics
5.44
-0.98
-15.26%
GALT
Galectin Therapeutics
2.50
1.22
95.31%
SLN
Silence Therapeutics
6.20
1.14
22.53%
HUMA
Humacyte
1.05
-1.48
-58.50%
VOR
Vor Biopharma
14.33
10.86
312.97%
Abeona Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair
Positive
Apr 7, 2026
On April 7, 2026, Abeona Therapeutics announced that Keith A. Goldan had been appointed as an independent member of its Board of Directors, effective April 1, 2026, and as Chairman of the Audit Committee. With more than two decades of financial le...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
Neutral
Mar 20, 2026
On March 16, 2026, Abeona Therapeutics Inc.’s board approved Third Amended and Restated Bylaws, replacing bylaws last updated on July 9, 2024, to clarify rules around calling, postponing, rescheduling, or canceling annual and special shareho...
Business Operations and StrategyProduct-Related Announcements
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
Positive
Mar 9, 2026
Abeona Therapeutics said on March 9, 2026, that commercial momentum is building for ZEVASKYN, its FDA-approved autologous gene therapy for wounds in patients with recessive dystrophic epidermolysis bullosa, following optimization of a key release ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.